Non-Hodgkin's lymphoma vaccine - CellGenix

Drug Profile

Non-Hodgkin's lymphoma vaccine - CellGenix

Alternative Names: IdioVax

Latest Information Update: 03 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CellGenix Technologie Transfer
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 05 Dec 2006 Phase-II clinical trials in Lymphoma in Germany (unspecified route)
  • 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Haematology (ASH-2003) have been added to the adverse events and Cancer immunogenicity section
  • 02 Oct 2001 Phase-I clinical trials for Lymphoma in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top